<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02514694</url>
  </required_header>
  <id_info>
    <org_study_id>LP0058-1114</org_study_id>
    <nct_id>NCT02514694</nct_id>
  </id_info>
  <brief_title>LEO 32731 - A Phase I Study in Healthy Subjects</brief_title>
  <official_title>LEO 32731 - A Phase I, Single-Blind, Placebo-Controlled, Single and Multiple Oral Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <brief_summary>
    <textblock>
      LEO 32731 (&quot;Study Drug&quot;) is an investigational drug which is being developed by LEO Pharma
      A/S (&quot;the Sponsor&quot;) for treatment of psoriasis. The aim (s) of this Study are to determine:

        -  The safety and tolerability of the Study Drug and any side effects that might be
           associated with it

        -  The Study will also measure how much of the Study Drug that gets into the blood and how
           long time it takes for the body to remove it.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety reported as number of Participants with Adverse Events</measure>
    <time_frame>16 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics reported as area under the plasma concentration versus time curve (AUC)</measure>
    <time_frame>16 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Psoriasis Vulgaris</condition>
  <arm_group>
    <arm_group_label>LEO 32731</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEO32731</intervention_name>
    <arm_group_label>LEO 32731</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Subjects will, prior to any study related activities, have given their written
             informed consent to participate in the study and to abide by the study restrictions.

          -  2. Subjects will be males or females of non-childbearing potential between 18 and 55
             years of age.

          -  3. Subjects will have a body mass index (BMI) between 18.0 and 30.0 kg/m2 inclusive.

          -  4. For Group C, subjects will be women of non-childbearing potential.

          -  5. Subjects must be in good health.

        Exclusion Criteria:

          -  1. Male subjects who are not willing, or whose partners are not willing, to use
             appropriate contraception.

          -  2. Subjects who have received any prescribed systemic or topical medication within 14
             days of the first dose administration unless in the opinion of the Investigator the
             medication will not interfere with the study procedures or compromise safety.

          -  3. Subjects who have used any non-prescribed systemic or topical medication (including
             herbal remedies) within 7 days of the first dose administration unless in the opinion
             of the Investigator the medication will not interfere with the study procedures or
             compromise safety.

          -  4. Subjects who have received any medications, including St John's Wort (or other
             dietary restriction, Section 6.2.3), known to chronically alter drug absorption or
             elimination processes within 30 days of the first dose administration unless in the
             opinion of the Investigator the medication will not interfere with the study
             procedures or compromise safety.

          -  5. Subjects with a significant history of drug allergy as determined by the
             Investigator.

          -  6. Subjects who have any clinically significant allergic disease (excluding non-active
             hayfever) as determined by the Investigator.

          -  7. Subjects who have a supine blood pressure and supine pulse rate at screening higher
             than 140/90 mmHg and 100 beats per minute (bpm), respectively, or lower than 90/50
             mmHg and 50 bpm, respectively.

          -  8. Subjects with a positive urine drug screen or alcohol breath test result at
             screening or first admission.

          -  9. Subjects with, or with a history of, any clinically significant neurological,
             gastrointestinal, renal, hepatic, cardiovascular, psychiatric, respiratory, metabolic,
             endocrine, haematological, dermatological or other major disorders as determined by
             the Investigator.

          -  10. Subjects who have had a clinically significant illness within 4 weeks of the start
             of dose administration as determined by the Investigator.

          -  11. Subjects who are known to have serum hepatitis, or who are carriers of the
             hepatitis B surface antigen (HBsAg) or hepatitis C antibody, or who have a positive
             result to the test for HIV antibodies.

          -  12. Active tuberculosis or history of incompletely treated tuberculosis, based on
             medical history or medical report.

          -  13. Subjects who, in the opinion of their General Practitioner (GP) or the
             Investigator, should not participate in the study.

          -  14. Subjects with one or more positive faecal occult blood test (immunochemical
             method) out of 2 assessments at the time between screening and Day-1 check-in.

          -  15. Subjects with â‰¥ 3 bowel movements/day.

          -  16. Subjects who have previously taken part in or withdrawn from this study.

          -  17. Subjects who, in the opinion of the Investigator, should not participate in the
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Covance CRU</name>
      <address>
        <city>Leeds</city>
        <zip>LS2 9LH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.leo-pharma.com/Home/Research-and-Development/Clinical-trial-disclosure/Clinical-trial-summaries-and-reports.aspx</url>
    <description>Clinical Trials at LEO Pharma</description>
  </link>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2015</study_first_submitted>
  <study_first_submitted_qc>July 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2015</study_first_posted>
  <last_update_submitted>May 1, 2017</last_update_submitted>
  <last_update_submitted_qc>May 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

